eFFECTOR Therapeutics Inc Sustainability Reports
eFFECTOR Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of selective translation regulator inhibitors (STRIs) as a novel class of therapies for cancer. The company initiated a wind-down of operations and terminated its entire workforce in mid-2024.
Sector: Manufacturing
Country: United States
Exchange: OTC Markets
LEI: 5493006L4NK7W3Z33415
1 reports from 2022 to 2022
